控制CD4+T细胞诱导的炎症细胞死亡 免疫逃避性瘤
Bastian Kruse1, Anthony C Buzzai1, Naveen Shridhar1
1Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.
Nature
|June 14, 2023
概括
CD4+ T细胞可以通过重编程髓状细胞来消除主要组织相容性复合体 (MHC) 缺陷的瘤. 这种先天免疫刺激补充了先进癌症免疫疗法的CD8+ T细胞疗法.
科学领域:
- 免疫学
- 癌症生物学
- 细胞免疫学
背景情况:
- 目前的癌症免疫疗法主要利用CD8+ T细胞来杀死瘤细胞.
- 主要组织相容性复合体 (MHC) 缺乏的瘤和免疫抑制的瘤微环境限制了当前免疫治疗的有效性.
- CD4+ 效应T 细胞表现出独立于 CD8+ T 细胞的抗瘤免疫力,但需要最大限度地发挥它们的功能.
研究的目的:
- 阐明CD4+T细胞可以根除MHC缺乏的瘤的机制.
- 确定利用CD4+T细胞在癌症免疫治疗中的全部潜力的策略.
主要方法:
- 研究了CD4+T细胞与瘤边缘的抗原呈现细胞的相互作用.
- 使用1型T辅助细胞指导的CD4+T细胞和先天免疫刺激.
- 分析了与瘤相关的骨髓细胞对效应表型的重新编程.
主要成果:
- 少数CD4+T细胞足以消除MHC缺乏的瘤.
- 在瘤侵袭边缘,CD4+ T细胞与MHC- II+CD11c+抗原呈现细胞相互作用.
- 天生的免疫刺激重新编程了髓状细胞,使其成为干扰素激活的抗原呈现细胞和表达iNOS的瘤杀伤细胞.
- CD4+ T细胞和瘤杀伤性骨髓细胞诱导了远程炎症细胞死亡,消除了对干扰素不反应和MHC缺乏的瘤.
结论:
- CD4+ T细胞与先天免疫刺激剂结合,可以消除MHC缺乏的瘤.
- 这种机制为增强现有的癌症免疫疗法提供了补充策略.
- 临床利用CD4+T细胞和先天免疫刺激剂可以通过克服当前治疗的局限性来推进癌症治疗.
更多相关视频
相关概念视频
Tumor Immunotherapy
575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Cytotoxic T Cells-mediated Immune Response
999
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
999
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
The Extrinsic Apoptotic Pathway
6.5K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.5K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


